The top 100 stock
market authors
selected for publication
market authors
selected for publication
Arena Pharmaceuticals Inc. (ARNA) ()
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Arena Pharmaceuticals Inc. (ARNA) by latest | most commented
- Vivus: Obesity Experimental Drug Has Promising Outlook
- Extreme FDA Trades: Another 18 Stocks Under 5 Bucks
- ADA Meeting 2009: Novel Diabetes Therapies Presented
- 6 Healthcare Stocks to Watch
- Arena Patients Keep Weight Off, Bodes Well for Partnership
- NeuroSearch: Experimental Obesity Drug to Begin Phase 3 Trials
- FDA Calendar Updates: Keryx Biopharma Announces Phase 2 Results
- Bio Medical Stock Sector is Where the Action Is
- A Biotech Triple Play: Dendreon, BioCryst and Arena
- Arena's Prospects Will Be in the Eye of the Suitors
- Arena Pharma Could Be on the Verge of Collapse
- Pending Clinical Trial Results: Ten Extreme Trades
- Orexigen's Contrave: Generic Would Be No Cheaper
- Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
- FDA and Clinical Trial Updates: Weight Loss, Diabetes and More
- Arena, The Aftermath
- Arena's Obesity Drug Not Likely to Make It
- Arena's New Obesity Drug: Safe, But Not Too Efficacious
- Monday's Options Recap
- Monday Options Update: GM, VIX, XLF, BAC & ARNA
- Arena's Financing Deal with Azimuth Is a Healthy Move
- Three Ways to Play Arena Pharmaceuticals
- Take Advantage of Market Confusion to Buy Orexigen Therapeutics
- Monday's Options Recap
- Monday Options Update: C, CMCSK, SWKS, ARNA,
- Friday's Options Recap
- Arena Study Results Crucial - For Safety, Watch and Wait
- Four Weighty Reasons to Invest in Vivus
- Arena Pharmaceuticals: Near Term Gamble May Be Worth It
- Vivus: A Bet on Well-Funded, Late-Stage Pipeline
- Know Your Options When Investing in Biotech Stocks
- Tuesday's Options Recap
- Options Recap for Monday
- Healthcare Investing: A Calendar of Expected Clinical Trial Results and Some Near Term Catalysts
- 9 Possible Pharma Deals for 2009
- 3 Top and Bottom Market Sectors for This Week
- Biotech Update: Arena Pharmaceuticals, Acusphere, Cephalon, ViroPharma, Auxilium
- Safety Data on Arena's Weight Loss Drug Could Pave Way for Good Partnership
- 2007 Biotech Performance Review
- Expecting a Strong Move in Arena Pharma
- Companies With The Most Analyst Attention & Affection
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largest
increase in followers
in the last 7 days-
1
Philip Davis
-
2
David Fry
-
3
TraderMark
-
4
Bill Gross
-
5
Tyler Durden
Fastest Climbers » -
1
-
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
